Add-on Acquisition • Life Science

Fujirebio Acquires ADx NeuroSciences

On June 23, 2022, Fujirebio acquired life science company ADx NeuroSciences for 40M EUR

Acquisition Context

This is Fujirebio’s 1st transaction in the Life Science sector.
This is Fujirebio’s largest (disclosed) transaction.
This is Fujirebio’s 1st transaction in Belgium.

Explore All 3111 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	June 23, 2022
Target	ADx NeuroSciences
Sector	Life Science
Buyer(s)	Fujirebio
Deal Type	Add-on Acquisition
Deal Value	40M EUR

Target Company

ADx NeuroSciences

Gent, Belgium

ADx NeuroSciences is an R&D-driven company specializing in the development of neurodegenerative biomarkers. Its expertise is used by pharmaceutical and diagnostic companies for the conception, development, production, and worldwide commercialization of novel biomarkers. These collaborations result in new diagnostic assays that support the development of promising drugs either by monitoring the drug effect or by selecting the right patients at a very early stage of the disease. These assays are used in neurodegenerative diseases like Alzheimer’s disease and Parkinson’s and can be applied to a variety of platforms for research up to IVD use. ADx NeuroSciences was formed in 2011 and is based in Gent, Belgium.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Fujirebio

Tokyo, Japan

Category	Company
Founded	1950
Sector	Medical Products

DESCRIPTION

Fujirebio focused on developing and marketing CSF biomarkers for Alzheimer’s disease testing, under the Innogenetics brand, over 25 years ago. It remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools. Fujirebio was formed in 1950 and is based in Tokyo, Japan.

Deal Context for Buyer	#
Overall	1 of 2
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 2
Country: Belgium	1 of 1
Year: 2022	1 of 1
Size (of disclosed)	1 of 1

FOLLOWING DEAL

DATE	TARGET	DEAL TYPE	VALUE
2025-06-23	Plasma Services Group Moorestown, New Jersey, United States Plasma Services Group specializes in the collection, screening, and supply of biological materials required for R&D and manufacturing in the in vitro diagnostics (IVD) and life science industries. The Group provides sera and other samples for materials of control reagents and calibrators for a wide range of diseases and offers sample collection services globally. Plasma Services Group was formed in 2004 and is based in Moorestown, New Jersey.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2025-06-23

Plasma Services Group

Moorestown, New Jersey, United States

Plasma Services Group specializes in the collection, screening, and supply of biological materials required for R&D and manufacturing in the in vitro diagnostics (IVD) and life science industries. The Group provides sera and other samples for materials of control reagents and calibrators for a wide range of diseases and offers sample collection services globally. Plasma Services Group was formed in 2004 and is based in Moorestown, New Jersey.

Buy

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Belgium M&A - 2022 M&A